Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy
A randomized clinical trial evaluating the use of a pedometer and brief exercise coaching in prostate cancer patients treated with androgen deprivation therapy.
- Trial name
- NCT00868868
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Groupe de recherche en Urologie de la Mauricie
Prostate Cancer
Exercise and Quality of Life During Androgen Deprivation Therapy
This study evaluates effects of supervised exercise in reducing adverse effects of hormonal treatment, increasing quality of life and in inducing a long-term change into more active lifestyle in prostate cancer patients on…
- Trial name
- NCT04050397
- Testing
- Progressive supervised weight training, Lecture
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Prostate Cancer, Hot Flashes
Embr Thermal Device for Hot Flash Management in Prostate Cancer
This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.
- Trial name
- NCT04892914
- Testing
- Embr thermal device
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Embr Labs, Inc.
Prostate Cancer
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer…
- Trial name
- ARN-509 (NCT03488810)
- Testing
- Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Cardiovascular Disease
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a…
- Trial name
- RADICALPC (NCT03127631)
- Testing
- Nutrition, Exercise, Smoking cessation
- Where
- 61 sites in United States, Australia and 7 more
- Volunteers
- 5,000 people
- Sponsor
- McMaster University
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
Prostate cancer patients treated with LHRH agonists (e.g., leuprolide) lose bone mineral density. This is similar to post-menopausal osteoporosis. Risedronate is approved to prevent osteoporosis.
- Trial name
- NCT00426777
- Testing
- risedronate, Control
- Where
- 21 sites in Canada
- Volunteers
- 160 people
- Sponsor
- CMX Research
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- DASL-HiCaP (NCT04136353)
- Testing
- Darolutamide, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Where
- 93 sites in United States, Australia and 4 more
- Volunteers
- 1,100 people
- Sponsor
- University of Sydney
Prostate Cancer
The Physical Exercise and Prostate Cancer Study
The purpose of this study is to determine the effectiveness of a four months strength training program on physical and psychological health in patients with prostate cancer during androgen deprivation therapy.
- Trial name
- PEPC (NCT00658229)
- Testing
- Strength training group
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Prostatic Neoplasms
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical…
- Trial name
- ENZAMET (NCT02446405)
- Testing
- Enzalutamide, NSAA, LHRHA or Surgical Castration
- Where
- 82 sites in United States, Australia and 4 more
- Volunteers
- 1,125 people
- Sponsor
- University of Sydney
Prostate Cancer, mHSPC
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread…
- Conditions
- Prostate Cancer, mHSPC, mCRPC
- Trial name
- ENHANCE (NCT07751133)
- Testing
- Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- University College, London
Prostate Cancer, Cardiotoxicity
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how those…
- Conditions
- Prostate Cancer, Cardiotoxicity, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Diseases
- Trial name
- PCT (NCT05096338)
- Testing
- Social Determinants of Health
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)
Current treatment options for high risk localized prostate cancer include radical prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation therapy.
- Trial name
- SATURN (NCT01953055)
- Testing
- Stereotactic ablative radiotherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are…
- Trial name
- NCT04619069
- Testing
- SBRT, Hormone therapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Recurrent Prostate Cancer
Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
It is estimated that one-third of the more than 7 million deaths from cancer worldwide are attributable to potentially modifiable risk factors, with 374,000 deaths preventable through diet modification alone.
- Trial name
- NCT03496805
- Testing
- MGE, ADT
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research study is to learn if treatment with standard systemic therapy (androgen deprivation therapy or bilateral orchiectomy) in combination with surgery or radiation therapy is more effective at…
- Trial name
- NCT01751438
- Testing
- Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires
- Where
- 4 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital